27 September 2024 Antibody-drug conjugates (ADCs) represent a significant advancement in cancer treatment, particularly within China's burgeoning oncology sector.
Shares of German pharma major Bayer were up 4.6% at 30.45 euros after it released positive early trial results for its Parkinson’s disease candidate. 27 September 2024
Shionogi said today that it has submitted a New Drug Application (NDA) in Japan for zuranolone, a treatment in development for major depressive disorder (MDD). 27 September 2024
CNS specialist Lundbeck has announced data from the TALISMAN natural history study, as well as additional data from the AMULET trial, of amlenetug, in multiple system atrophy (MSA) at the International Congress of Parkinson's Disease and Movement disorders in Philadelphia, USA. 27 September 2024
Repair Biotechnologies, a company developing therapies to reverse atherosclerotic plaque, has entered into a collaboration with Genevant Sciences, a specialist in nucleic acid delivery technology. 27 September 2024
China’s National Medical Products Administration (NMPA) has approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD). 27 September 2024
Chicago, USA-based ARCH Venture Partners revealed it has closed the ARCH Venture Fund XIII, a venture capital fund with more than $3 billion to support the founding and growth of early-stage biotechnology companies. 27 September 2024
US virology and immunology company Enanta Pharmaceuticals has given further weight to its claims to have the leading portfolio of potent respiratory syncytial virus (RSV) replication inhibitors 27 September 2024
Sage Therapeutics has announced that Biogen has terminated its partnership on the SAGE-324 program, following the recent failure of the drug in a Phase II study for the treatment of essential tremor. 27 September 2024
A US Food and Drug Administration advisory committee meeting has recommended restricting the use of PD-1 inhibitors, in a move which could affect blockbuster products such as Bristol Myers Squibb's Opdivo (nivolumab) and Merck & Co's Keytruda (pembrolizumab). 27 September 2024
The US Food and Drug Administration yesterday approved pharma major Bristol Myers Squibb’s Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults. 27 September 2024
USA-based biotech funder and incubator Flagship Pioneering yesterday unveiled Mirai Bio, a company pioneering the first open end-to-end platform for the biotech industry to enable the co-creation of fully optimized genetic medicines. 27 September 2024
Antibody-drug conjugates (ADCs) represent a significant advancement in cancer treatment, particularly within China's burgeoning oncology sector. 27 September 2024
US drugmaker AbbVie has announced positive topline results from its pivotal Phase III TEMPO-1 trial for tavapadon as a monotherapy in early Parkinson's disease. 26 September 2024
Evaxion Biotech has entered into an option and license agreement with MSD (tradename of Merck & Co outside of the USA and Canada), for two pre-clinical vaccine candidates. 26 September 2024
Danish CNS specialist Lundbeck and US privately-held biotech Iambic Therapeutics today announced a strategic research collaboration to focus on discovery of a small molecule therapeutic for the treatment of migraine. 26 September 2024
The generics and biosimilars trade group, Medicines for Europe, has put out a strong message amid ongoing discussions on a European Union (EU) Critical Medicines Act. 26 September 2024
Pfizer (NYSE: PFE) has announced the withdrawal of Oxbryta (voxelotor), a treatment for sickle cell disease (SCD), from all global markets. 26 September 2024
US pharma giant Pfizer said yesterday it is seeking Emergency Use Authorization (EUA) of its investigational oral antiviral candidate, Paxlovid (PF-07321332; ritonavir), for the treatment of mild to moderate COVID-19 in patients at increased risk of hospitalizations or death. 17 November 2021
US biotech Biogen surprised industry watchers, with the announcement that Alfred (Al) Sandrock Jr, head of research and development, will retire from the company effective December 31, 2021. 17 November 2021
More than 20,000 strokes and 5,000 deaths could be averted after NHS England struck new agreements to expand life-saving blood thinning drugs, chief executive Amanda Pritchard announced yesterday. 17 November 2021
The Institute for Clinical and Economic Review (ICER) regularly calls out drugmakers in certain therapy areas for introducing drugs to the market at prices that exceed its estimates of what they are worth. 16 November 2021
US pharma giant Pfizer has had enormous success with its COVID-19 vaccine Comirnaty, developed and marketed with Germany’s BioNTech, and is now turning to its oral antiviral to treat the coronavirus infection, Paxlovid (ritonavir), for which it released stunning trial results last week. 16 November 2021
In the early days of the coronavirus pandemic, many drugmakers saw major share price declines as investors got to grips with the likely impact on prescribing, developing medicines, and supply chain interruptions. 16 November 2021
Czech immuno-oncology company SOTIO Biotech, which is owned by PPF Group, today announced an exclusive, target-specific license and option agreement with South Korean biotech LegoChem Biosciences, a company focused on developing its clinical-stage platform technology enabling antibody-drug conjugates (ADCs). 16 November 2021
While injectable PCSK9 inhibitors have long promised an effective way to lower LDL cholesterol levels, relatively low uptake has been blamed on high prices and a burdensome mode of administration. 16 November 2021
The neuromyelitis optica spectrum disorder (NMOSD) therapeutics market is highly genericized, with corticosteroids and immunosuppressants currently accounting for the highest portion of prescribed drugs in China. 16 November 2021
US DNA synthesis firm Twist Bioscience has launched Revelar Biotherapeutics, an independently operated, new biotechnology company to develop and commercialize an antibody, discovered and optimized by its Twist Biopharma division, that neutralizes all known variants of concern of the SARS-CoV-2 virus in pre-clinical studies. 16 November 2021
The Russian drugmaker R-Pharm plans to produce Sputnik V vaccine in the European Union and has received a three-year loan of 50 million ($57 million) to expand the company's production in Illertissen, Germany. 16 November 2021
German pharma and life sciences firm Merck KGaA and the Pediatric Praziquantel Consortium today announced that the pivotal Phase III trial for arpraziquantel, a potential new treatment option for the neglected tropical disease schistosomiasis, has met the primary endpoint of clinical cure in children three months to six years of age. 16 November 2021
Dutch fatty acid expert NorthSea Therapeutics has presented positive interim data from a Phase IIb study of its non-alcoholic steatohepatitis (NASH) candidate, icosabutate. 16 November 2021
German drugmaker STADA Arzneimittel plans to continue an active development in the Russian pharmaceutical market in the coming years, considering it as one of the most promising for its further growth, reports The Pharma Letter’s local correspondent. 16 November 2021
A set of guidelines that will provide a well-defined framework and guiding principle to facilitate sharing of biological information and data generated by research groups in India has been released by the government. 16 November 2021
Australian off-the-shelf cell therapy specialist Mesoblast saw its shares gain nearly 12% to A$1.90 today, as it released positive new results from the landmark Phase III study of rexlemestrocel-L in 565 patients with chronic heart failure (CHF) with reduced ejection fraction (HFrEF). 15 November 2021
Japanese mid-sized pharma company Kyowa Kirin today announced that, following a re-examination procedure, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion for istradefylline as an add-on treatment to levodopa (L-Dopa) based regimens in adults living with Parkinson’s, experiencing end-of-dose motor fluctuations. 15 November 2021